Integrative medicine最新文献

Blastocystis hominis (B. hominis) remains the most common parasite identified through stool examination. A clinician will undoubtedly encounter the presence of this parasite numerous times in their career. Thus, it is vital to know if this organism is a 'friend or foe', or in other words, whether it is a commensal or a pathogen. This will help clinicians decide whether to treat or not. This literature review discusses the best available evidence of the association of B. hominis and two diseases- irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Particularly, focus has been paid to the effect of antimicrobial therapy in improving disease activity/symptoms and concluding on the pathogenicity of B. hominis based on in vitro, observational studies, and randomized controlled trials. Most importantly, the review presents a concise set of recommendations for when and how to treat B. hominis in a patient presenting gastrointestinal ailments.

This case report explores the diagnostic challenges in evaluating first-time seizures by highlighting the importance of differentiating between provoked and unprovoked seizures. The patient, a 65-year-old female, experienced her first seizure during a yoga retreat in Costa Rica, influenced by a perfect storm of overlapping factors such as traveler's diarrhea, alcohol consumption, and THC use. Comprehensive evaluation and laboratory assessments revealed an elevated hematocrit and borderline magnesium deficiency. Despite limitations in reporting accuracy and the lack of immediate medical transfer, these findings did not hinder the diagnostic process. This episode, classified as a provoked seizure, highlights the necessity of a detailed case history when evaluating a presumed first-time seizure, targeted electrolyte assessment, and hydration strategies to inform clinical decision-making.

Rheumatoid arthritis is increasingly being recognized as the synovial manifestation of a group of systemic autoinflammatory conditions known as immune-mediated inflammatory diseases. While each of these conditions displays unique diagnostic signs and symptoms based on the tissue targeted by inflammation, most immune-mediated inflammatory diseases share common features, including their immune-signaling pathways. Owing to these similarities, great advances have emerged in the past few decades using therapies designed to block downstream inflammatory mediators (eg, cytokine-blocking biologics, Janus Kinase (JAK) inhibitors). Unfortunately, fewer advances have been made in therapies that have the potential to target the upstream antecedents and triggers of these complex inflammatory diseases, such as the immunologic chain of events triggered by intestinal hyperpermeability (ie, leaky gut) or gastrointestinal dysbiosis (ie, alterations in the gut microbiota). In the past few decades, intestinal hyperpermeability has emerged as an important antecedent for a wide range of chronic immunological and metabolic conditions, including celiac disease, obesity, cardiovascular disease, and a number of immune-mediated inflammatory diseases such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis. In this narrative review, we discuss the growing awareness that biomarkers of intestinal permeability are frequently associated with non-gastrointestinal immune-mediated inflammatory diseases, particularly those associated with the gut-joint axis, such as rheumatoid arthritis. We suggest that measures of intestinal permeability, along with lifestyle and nutrient interventions that target gut-barrier function, may be important adjunctive clinical tools to help patients with rheumatoid arthritis achieve and maintain remission.

Microplastics and nanoplastics are pervasive in the environment and pollute every tissue in the body. Emerging research demonstrates a positive correlation between tissue concentrations of microplastics and several common diseases. The sources of exposure are well understood and can be controlled. However, there appear to be no clinical trials for eliminating microplastics from tissues.

We present a case of acne successfully treated with a topical spray containing live bacteria. The live bacteria used in the spray contain CRISPR, and adaptive immune system in the bacteria that are used to disable viral replication. Because acne skin contains bacteria in the microbiome where a shift toward non-CRISPR bacteria occurs, these bacteria are susceptible to bacteriophage infection and lysogeny. Normalizing the bacterial microbiome to one containing more CRISPR-containing bacteria renormalizes the microbiome by killing inflammation-causing bacteriophage infecting the non-CRISPR bacteria associated with acne.